迪哲医药: 迪哲医药：关于高级管理人员减持股份结果公告

Summary of Key Points Core Viewpoint - The announcement details the share reduction results of Dr. Chang Shih-Ying, the Vice President of Dize Pharmaceutical Co., Ltd., indicating a completed share reduction plan due to personal financial needs. Group 1: Shareholding Information - Before the reduction plan, Dr. Chang held 65,000 shares, representing 0.0141% of the company's total share capital, acquired through an equity incentive plan [1] - The reduction plan allowed for a maximum of 16,000 shares to be sold, which would account for no more than 0.0035% of the total share capital [1] Group 2: Reduction Results - As of July 4, 2025, Dr. Chang had reduced his holdings by 16,155 shares, which is 0.0035% of the current total share capital [2] - The reduction occurred between June 25, 2025, and July 4, 2025, through centralized bidding [2] - The share price during the reduction ranged from 58.9 to 66 yuan per share, totaling approximately 990,733.82 yuan in proceeds [2] Group 3: Compliance with Reduction Plan - The actual reduction exceeded the initially planned maximum by 155 shares, but did not surpass 25% of the total shares held [3] - The reduction plan was fully executed without early termination [3]